Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Auxira Health Raises $7.8M in Seed Funding
Auxira Health, a Chicago, IL-based virtual cardiology company, raised $7.8M in Seed funding.
The round was led by Route 66 Ventures and Abundant Venture Partners with participation from DigiTx Partners, American Heart Association Ventures, Ensemble Innovation Ventures, and City Light Capital.
The company intends to use the funds to expand its footprint with additional cardiology partners, deepen its operational and technology infrastructure, and continue hiring clinicians and support staff to meet accelerating demand.
Led by CEO Inna Plumb, Auxira Health is a virtual cardiology company developing an integrated virtual extension model that pairs advanced practice providers (APPs), medical assistants (MAs), and registered nurses (RNs) with cardiology teams, embedding them virtually as members of the practice…
Full release here, originally announced December 15th, 2025.
Vitalis Ventures Announces $15 Million Strategic Funding for Drive Health to Accelerate Avery, the Clinical Workflow AI
Vitalis Ventures, an investment platform focused on AI-enabled healthcare technology companies advancing next-generation care delivery, announces a strategic $15 million investment in Drive Health, the healthcare technology company behind Avery, a Google-powered agentic AI platform designed to transform how patients navigate care and alleviate the workload placed on clinicians. The total investment includes an additional tranche scheduled to close in Q1 2026. Vitalis Ventures partnered with Inside Capital Partners on the transaction.
This latest investment from Vitalis Ventures brings the total capital committed to Drive Health to $26+ million. The funding marks a significant step in Drive Health’s expansion as the company looks toward a Series A in 2026 and continues to advance its collaboration with Google to deliver scalable, clinically aligned AI support across health systems, managed care organizations, and population health plans. Upon completion of the second tranche, Vitalis Ventures will join Drive Health’s Board of Directors, with a focus on strengthening and developing partnerships throughout the healthcare ecosystem.
“This partnership marks a major inflection point for Drive Health,” said Kevin Longoria, CEO at Drive Health. “Vitalis brings real operational depth, health-system experience, and the long-term vision needed to scale Avery responsibly. With their support, and through our continued work with Google, we are accelerating our ability to deliver safe, accessible, and compassionate AI support to healthcare facilities and patients nationwide.”
“Drive Health developed the lowest latency, most comprehensive and clinically aligned workflow automation platform in the market, with the potential to meaningfully reshape how care teams manage communication and follow-up,” said Elliot LaBreche, Founder and CEO at Vitalis…
Full release here, originally announced December 17th, 2025.
Wearlinq Raises $14M Series A to Combat America’s Leading Cause of Death with the First and Only Wireless 6-Lead Cardiac Monitor
Wearlinq, a leading provider of wearable health monitoring and diagnosis solutions, today announced $14 million in Series A funding led by AIX Ventures, along with SpringTide, Berkeley Catalyst Fund, Lightscape Partners, Amino Capital, and others (complete list below). The company is already helping thousands of patients monitor and treat heart disease, the leading cause of death in the United States. Alongside the equity round, the company raised $5M in venture debt to support its growth.
Cardiologists’ Problem: No Accurate Way to Monitor Patients Remotely
Heart disease is the leading cause of death in the U.S., claiming 1 in 3 lives. Despite the significant human and financial costs, cardiologists still lack a high-quality method for wirelessly monitoring hearts at home or in the hospital. At home, most devices track heart rate rather than the electrical rhythm. Heart rate alone can’t catch many arrhythmias or the subtle changes that signal rising risk. In hospitals, wired telemetry is bulky and brief, and single-lead patches often miss intermittent events. The result is a system where patients take devices off, doctors order repeat tests, and heart disease continues to claim millions more lives.
“WearLinq provides a leap forward, bringing multi-lead, high-fidelity arrhythmia data and near real-time patient data outside of the hospital and clinic,” said Albert Rogers, Electrophysiologist at Stanford & Wearlinq Co-Founder…
Full release here, originally announced December 17th, 2025.
No comments:
Post a Comment